Top

Published in:

08-04-2024 | Aortic Valve Stenosis | Research

Identification of Circulating Inflammatory Proteins Associated with Calcific Aortic Valve Stenosis by Multiplex Analysis

Authors: Rui Lin, Yuexin Zhu, Weiyao Chen, Zhiao Wang, Yuan Wang, Jie Du

Published in: Cardiovascular Toxicology | Issue 5/2024

Abstract

Calcific aortic valve stenosis (CAVS) is characterized by increasing inflammation and progressive calcification in the aortic valve leaflets and is a major cause of death in the aging population. This study aimed to identify the inflammatory proteins involved in CAVS and provide potential therapeutic targets. We investigated the observational and causal associations of 92 inflammatory proteins, which were measured using affinity-based proteomic assays. Firstly, the case–control cohort identified differential proteins associated with the occurrence and progression of CAVS. Subsequently, we delved into exploring the causal impacts of these associated proteins through Mendelian randomization. This involved utilizing genetic instruments derived from cis-protein quantitative loci identified in genome-wide association studies, encompassing a cohort of over 400,000 individuals. Finally, we investigated the gene transcription and protein expression levels of inflammatory proteins by single-cell and immunohistochemistry analysis. Multivariate logistic regression and spearman's correlation analysis showed that five proteins showed a significant positive correlation with disease severity. Mendelian randomization showed that elevated levels of two proteins, namely, matrix metallopeptidase-1 (MMP1) and sirtuin 2 (SIRT2), were associated with an increased risk of CAVS. Immunohistochemistry and single-cell transcriptomes showed that expression levels of MMP1 and SIRT2 at the tissue and cell levels were significantly higher in calcified valves than in non-calcified control valves. These findings indicate that MMP1 and SIRT2 are causally related to CAVS and open up the possibility for identifying novel therapeutic targets.

Available only for authorised users

Carabello, B. A., & Paulus, W. J. (2009). Aortic stenosis. Lancet (London, England), 373, 956–966. https://doi.org/10.1016/s0140-6736(09)60211-7CrossRefPubMed

Yadgir, S., Johnson, C. O., Aboyans, V., Adebayo, O. M., Adedoyin, R. A., Afarideh, M., Alahdab, F., Alashi, A., Alipour, V., Arabloo, J., et al. (2020). Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation, 141, 1670–1680. https://doi.org/10.1161/circulationaha.119.043391CrossRefPubMed

Otto, C. M., & Prendergast, B. (2014). Aortic-valve stenosis–from patients at risk to severe valve obstruction. New England Journal of Medicine, 371, 744–756. https://doi.org/10.1056/NEJMra1313875CrossRefPubMed

Peeters, F., Meex, S. J. R., Dweck, M. R., Aikawa, E., Crijns, H., Schurgers, L. J., & Kietselaer, B. (2018). Calcific aortic valve stenosis: Hard disease in the heart: A biomolecular approach towards diagnosis and treatment. European Heart Journal, 39, 2618–2624. https://doi.org/10.1093/eurheartj/ehx653CrossRefPubMed

Lindman, B. R., Bonow, R. O., & Otto, C. M. (2013). Current management of calcific aortic stenosis. Circulation Research, 113, 223–237. https://doi.org/10.1161/circresaha.111.300084CrossRefPubMedPubMedCentral

Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022). Calcific aortic valve disease: From molecular and cellular mechanisms to medical therapy. European Heart Journal, 43, 683–697. https://doi.org/10.1093/eurheartj/ehab757CrossRefPubMed

Yutzey, K. E., Demer, L. L., Body, S. C., Huggins, G. S., Towler, D. A., Giachelli, C. M., Hofmann-Bowman, M. A., Mortlock, D. P., Rogers, M. B., Sadeghi, M. M., et al. (2014). Calcific aortic valve disease. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.114.302523CrossRefPubMedPubMedCentral

Driscoll, K., Cruz, A. D., & Butcher, J. T. (2021). Inflammatory and biomechanical drivers of endothelial-interstitial interactions in calcific aortic valve disease. Circulation Research, 128, 1344–1370. https://doi.org/10.1161/circresaha.121.318011CrossRefPubMedPubMedCentral

García-Rodríguez, C., Parra-Izquierdo, I., Castaños-Mollor, I., López, J., San Román, J. A., & Sánchez, Crespo M. (2018). Toll-Like receptors, inflammation, and calcific aortic valve disease. Front Physiol, 9, 201. https://doi.org/10.3389/fphys.2018.00201CrossRefPubMedPubMedCentral

10.

Galante, A., Pietroiusti, A., Vellini, M., Piccolo, P., Possati, G., De Bonis, M., Grillo, R. L., Fontana, C., & Favalli, C. (2001). C-reactive protein is increased in patients with degenerative aortic valvular stenosis. Journal of the American College of Cardiology, 38, 1078–1082. https://doi.org/10.1016/s0735-1097(01)01484-xCrossRefPubMed

11.

Small, A., Kiss, D., Giri, J., Anwaruddin, S., Siddiqi, H., Guerraty, M., Chirinos, J. A., Ferrari, G., & Rader, D. J. (2017). Biomarkers of calcific aortic valve disease. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.116.308615CrossRefPubMedPubMedCentral

12.

Wallentin, L., Eriksson, N., Olszowka, M., Grammer, T. B., Hagström, E., Held, C., Kleber, M. E., Koenig, W., März, W., Stewart, R. A. H., et al. (2021). Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Medicine, 18, e1003513. https://doi.org/10.1371/journal.pmed.1003513CrossRefPubMedPubMedCentral

13.

Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., Oerton, E., Cook, J., Stewart, I. D., Kerrison, N. D., et al. (2021). Mapping the proteo-genomic convergence of human diseases. Science. https://doi.org/10.1126/science.abj1541CrossRefPubMedPubMedCentral

14.

Zhang, J., Dutta, D., Köttgen, A., Tin, A., Schlosser, P., Grams, M. E., Harvey, B., Yu, B., Boerwinkle, E., Coresh, J., et al. (2022). Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nature Genetics, 54, 593–602. https://doi.org/10.1038/s41588-022-01051-wCrossRefPubMedPubMedCentral

15.

Czesnikiewicz-Guzik, M., Osmenda, G., Siedlinski, M., Nosalski, R., Pelka, P., Nowakowski, D., Wilk, G., Mikolajczyk, T. P., Schramm-Luc, A., Furtak, A., et al. (2019). Causal association between periodontitis and hypertension: Evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. European Heart Journal, 40, 3459–3470. https://doi.org/10.1093/eurheartj/ehz646CrossRefPubMedPubMedCentral

16.

Henry, A., Gordillo-Marañón, M., Finan, C., Schmidt, A. F., Ferreira, J. P., Karra, R., Sundström, J., Lind, L., Ärnlöv, J., Zannad, F., et al. (2022). Therapeutic targets for heart failure identified using proteomics and mendelian randomization. Circulation, 145, 1205–1217. https://doi.org/10.1161/circulationaha.121.056663CrossRefPubMedPubMedCentral

17.

Zheng, K. H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W. S. A., Doris, M. K., White, A. C., Timmers, N. K. L. M., Hjortnaes, J., Rogers, M. A., et al. (2019). Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. Journal of the American College of Cardiology, 73, 2150–2162. https://doi.org/10.1016/j.jacc.2019.01.070CrossRefPubMedPubMedCentral

18.

Otto, C. M. (2006). Valvular aortic stenosis: disease severity and timing of intervention. Journal of the American College of Cardiology, 47, 2141–2151. https://doi.org/10.1016/j.jacc.2006.03.002CrossRefPubMed

19.

Egervall, K., Rosso, A., & Elmståhl, S. (2021). Association between cardiovascular disease- and inflammation-related serum biomarkers and poor lung function in elderly. Clinical Proteomics, 18, 23. https://doi.org/10.1186/s12014-021-09329-7CrossRefPubMedPubMedCentral

20.

Zhao, J. H., Stacey, D., Eriksson, N., Macdonald-Dunlop, E., Hedman, Å. K., Kalnapenkis, A., Enroth, S., Cozzetto, D., Digby-Bell, J., Marten, J., et al. (2023). Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nature Immunology, 24, 1540–1551. https://doi.org/10.1038/s41590-023-01588-wCrossRefPubMedPubMedCentral

21.

Xu, K., Xie, S., Huang, Y., Zhou, T., Liu, M., Zhu, P., Wang, C., Shi, J., Li, F., Sellke, F. W., et al. (2020). Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 2910–2921. https://doi.org/10.1161/atvbaha.120.314789CrossRefPubMed

22.

Xu, F., Yu, E.Y.-W., Cai, X., Yue, L., Jing, L.-p, Liang, X., Fu, Y., Miao, Z., Yang, M., Shuai, M., et al. (2023). Genome-wide genotype-serum proteome mapping provides insights into the cross-ancestry differences in cardiometabolic disease susceptibility. Nature Communications. https://doi.org/10.1038/s41467-023-36491-3CrossRefPubMedPubMedCentral

23.

Võsa, U., Claringbould, A., Westra, H. J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nature Genetics, 53, 1300–1310. https://doi.org/10.1038/s41588-021-00913-zCrossRefPubMedPubMedCentral

24.

Yu, J., Wang, Z., Bao, Q., Lei, S., You, Y., Yin, Z., & Xie, X. (2022). Global burden of calcific aortic valve disease and attributable risk factors from 1990 to 2019. Frontiers in Cardiovascular Medicine, 9, 1003233. https://doi.org/10.3389/fcvm.2022.1003233CrossRefPubMedPubMedCentral

25.

Head, S. J., Çelik, M., & Kappetein, A. P. (2017). Mechanical versus bioprosthetic aortic valve replacement. European Heart Journal, 38, 2183–2191. https://doi.org/10.1093/eurheartj/ehx141CrossRefPubMed

26.

Dhayni, K., Chabry, Y., Hénaut, L., Avondo, C., Boudot, C., Ouled-Haddou, H., Bigot-Corbel, E., Touati, G., Caus, T., Messaoudi, H., et al. (2023). Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXC motif chemokine receptor 2. Cardiovascular Research, 119, 2355–2367. https://doi.org/10.1093/cvr/cvad117CrossRefPubMed

27.

Yang, Z., Zhang, J., Zhu, Y., Zhang, C., Li, G., Liu, S., Du, J., Han, Y., & You, B. (2023). IL-17A induces valvular endothelial inflammation and aggravates calcif ic aortic valve disease. Biochemical and Biophysical Research Communications, 672, 145–153. https://doi.org/10.1016/j.bbrc.2023.04.079CrossRefPubMed

28.

Gollmann-Tepeköylü, C., Graber, M., Hirsch, J., Mair, S., Naschberger, A., Pölzl, L., Nägele, F., Kirchmair, E., Degenhart, G., Demetz, E., et al. (2023). Toll-Like receptor 3 mediates aortic stenosis through a conserved mechanism of calcification. Circulation, 147, 1518–1533. https://doi.org/10.1161/circulationaha.122.063481CrossRefPubMed

29.

Pohle, K., Mäffert, R., Ropers, D., Moshage, W., Stilianakis, N., Daniel, W. G., & Achenbach, S. (2001). Progression of aortic valve calcification. Circulation, 104, 1927–1932. https://doi.org/10.1161/hc4101.097527CrossRefPubMed

30.

Chang, K., Yokose, C., Tenner, C., Oh, C., Donnino, R., Choy-Shan, A., Pike, V. C., Shah, B. D., Lorin, J. D., Krasnokutsky, S., et al. (2017). Association Between Gout and Aortic Stenosis. The American Journal of Medicine, 130, 230.e231-230.e238. https://doi.org/10.1016/j.amjmed.2016.09.005CrossRef

31.

Malik, M. H. A., Jury, F., Bayat, A., Ollier, W. E. R., & Kay, P. R. (2007). Genetic susceptibility to total hip arthroplasty failure: A preliminar y study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Annals of the Rheumatic Diseases, 66, 1116–1120. https://doi.org/10.1136/ard.2006.062018CrossRefPubMedPubMedCentral

32.

Miller, J. D., Weiss, R. M., & Heistad, D. D. (2011). Calcific aortic valve stenosis: methods, models, and mechanisms. Circulation Research. https://doi.org/10.1161/CIRCRESAHA.110.234138CrossRefPubMedPubMedCentral

33.

Helske, S., Syväranta, S., Lindstedt, K. A., Lappalainen, J., Öörni, K., Mäyränpää, M. I., Lommi, J., Turto, H., Werkkala, K., Kupari, M., et al. (2006). Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.0000228824.01604.63CrossRefPubMed

34.

Di Vito, A., Donato, A., Presta, I., Mancuso, T., Brunetti, F. S., Mastroroberto, P., Amorosi, A., Malara, N., & Donato, G. (2021). Extracellular matrix in calcific aortic valve disease: architecture, dynamic and perspectives. International Journal of Molecular Sciences, 22, 913. https://doi.org/10.3390/ijms22020913CrossRefPubMedPubMedCentral

35.

Matilla, L., Roncal, C., Ibarrola, J., Arrieta, V., García-Peña, A., Fernández-Celis, A., Navarro, A., Álvarez, V., Gainza, A., Orbe, J., et al. (2020). A Role for MMP-10 (Matrix Metalloproteinase-10) in calcific aortic valve stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 1370–1382. https://doi.org/10.1161/atvbaha.120.314143CrossRefPubMed

36.

Zhang, Y., Wang, X., Li, X.-K., Lv, S.-J., Wang, H.-P., Liu, Y., Zhou, J., Gong, H., Chen, X.-F., Ren, S.-C., et al. (2023). Sirtuin 2 deficiency aggravates ageing-induced vascular remodelling in humans and mice. European Heart Journal. https://doi.org/10.1093/eurheartj/ehad381CrossRefPubMedPubMedCentral

37.

Wang, Y., Yang, J., Hong, T., Chen, X., & Cui, L. (2019). SIRT2: Controversy and multiple roles in disease and physiology. Ageing Research Reviews, 55, 100961. https://doi.org/10.1016/j.arr.2019.100961CrossRefPubMed

38.

Lynn, E. G., McLeod, C. J., Gordon, J. P., Bao, J., & Sack, M. N. (2008). SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via regulation of 14–3-3 zeta and BAD in H9c2 cells. FEBS Letters, 582, 2857–2862. https://doi.org/10.1016/j.febslet.2008.07.016CrossRefPubMedPubMedCentral

39.

Amigo, I., & Kowaltowski, A. J. (2014). Dietary restriction in cerebral bioenergetics and redox state. Redox Biology, 2, 296–304. https://doi.org/10.1016/j.redox.2013.12.021CrossRefPubMedPubMedCentral

40.

Macaulay, V. M., O’Byrne, K. J., Saunders, M. P., Braybrooke, J. P., Long, L., Gleeson, F., Mason, C. S., Harris, A. L., Brown, P., & Talbot, D. C. (1999). Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 5, 513–520.PubMed

41.

Vandenbroucke, R. E., & Libert, C. (2014). Is there new hope for therapeutic matrix metalloproteinase inhibition? Nature Reviews Drug Discovery, 13, 904–927. https://doi.org/10.1038/nrd4390CrossRefPubMed

42.

Guclu, E., Inan, S. Y., & Vural, H. C. (2022). The sirtuin 2 inhibitor AK-7 leads to an antidepressant-like effect in mice via upregulation of CREB1, BDNF, and NTRK2 pathways. Molecular Neurobiology, 59, 7036–7044. https://doi.org/10.1007/s12035-022-03026-8CrossRefPubMed

43.

Tomášek, A., Maňoušek, J., Kuta, J., Hlásenský, J., Křen, L., Šindler, M., Zelený, M., Kala, P., & Němec, P. (2023). Metals and trace elements in calcified valves in patients with acquire d severe aortic valve stenosis: Is there a connection with the degeneration process? Journal of Personalized Medicine, 13, 320. https://doi.org/10.3390/jpm13020320CrossRefPubMedPubMedCentral

44.

Bondy, S. C. (2016). Metal toxicity, inflammation and oxidative stress. Springer.CrossRef

45.

Flora, S. J. (2014). Toxic metals: health effects, & therapeutic measures. Journal of Biomedical Science, 1, 48–64.

Title: Identification of Circulating Inflammatory Proteins Associated with Calcific Aortic Valve Stenosis by Multiplex Analysis
Authors: Rui Lin
Yuexin Zhu
Weiyao Chen
Zhiao Wang
Yuan Wang
Jie Du
Publication date: 08-04-2024
Publisher: Springer US
Keyword: Aortic Valve Stenosis
Published in: Cardiovascular Toxicology / Issue 5/2024
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-024-09854-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Identification of Circulating Inflammatory Proteins Associated with Calcific Aortic Valve Stenosis by Multiplex Analysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Acute High-Output Heart Failure with Pulmonary Hypertension and Severe Liver Injury Caused by Amlodipine Poisoning: A Case Report

Opioids-Induced Long QT Syndrome: A Challenge to Cardiac Health

Could Pan-Immune-Inflammation Value be a Marker for the Diagnosis of Coronary Slow Flow Phenomenon?

Addressing Cardiovascular Toxicity Risk of Electronic Nicotine Delivery Systems in the Twenty-First Century: “What Are the Tools Needed for the Job?” and “Do We Have Them?”

N-acetylcysteine Protects Against Myocardial Ischemia–Reperfusion Injury Through Anti-ferroptosis in Type 1 Diabetic Mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page